10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2020 | |||
Consolidated Statement of Earnings | |||
Period Ending Dec 31, 2020 10-K (Filed: Feb 19, 2021) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
| Net sales | $ 34,608 | 31,904 | 30,578 |
| Cost of products sold, excluding amortization of intangible assets | 15,003 | 13,231 | 12,706 |
| Amortization of intangible assets | 2,132 | 1,936 | 2,178 |
| Research and development | 2,420 | 2,440 | 2,300 |
| Selling, general and administrative | 9,696 | 9,765 | 9,744 |
| Total Operating Cost and Expenses | 29,251 | 27,372 | 26,928 |
| Operating Earnings | 5,357 | 4,532 | 3,650 |
| Interest expense | 546 | 670 | 826 |
| Interest income | (46) | (94) | (105) |
| Net foreign exchange (gain) loss | (8) | 7 | 28 |
| Debt extinguishment costs | 63 | 167 | |
| Other (income) expense, net | (103) | (191) | (139) |
| Earnings from Continuing Operations Before Taxes | 4,968 | 4,077 | 2,873 |
| Taxes on Earnings from Continuing Operations | 497 | 390 | 539 |
| Earnings from Continuing Operations | 4,471 | 3,687 | 2,334 |
| Net Earnings from Discontinued Operations, net of taxes | 24 | 34 | |
| Net Earnings | 4,495 | 3,687 | 2,368 |
| Basic Earnings Per Common Share -- | |||
| Continuing Operations | 2.51 | 2.07 | 1.32 |
| Discontinued Operations | 0.01 | 0.02 | |
| Net Earnings | 2.52 | 2.07 | 1.34 |
| Diluted Earnings Per Common Share -- | |||
| Continuing Operations | 2.49 | 2.06 | 1.31 |
| Discontinued Operations | 0.01 | 0.02 | |
| Net Earnings | 2.50 | 2.06 | 1.33 |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share | 1,773 | 1,768 | 1,758 |
| Dilutive Common Stock Options | 13 | 13 | 12 |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options | 1,786 | 1,781 | 1,770 |
| Outstanding Common Stock Options Having No Dilutive Effect | 9 | 61 | |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2020 | |||
Consolidated Statement of Comprehensive Income | |||
Period Ending Dec 31, 2020 10-K (Filed: Feb 19, 2021) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
| Net Earnings | $ 4,495 | 3,687 | 2,368 |
| Foreign currency translation gain (loss) adjustments | 65 | (12) | (1,460) |
| Net actuarial gains (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, net of taxes of $(79) in 2020, $(238) in 2019 and $47 in 2018 | (331) | (814) | 132 |
| Net (losses) gains on derivative instruments designated as cash flow hedges, net of taxes of $(87) in 2020, $(17) in 2019 and $50 in 2018 | (215) | (53) | 136 |
| Other Comprehensive Income (Loss) | (481) | (879) | (1,192) |
| Comprehensive Income | 4,014 | 2,808 | 1,176 |
| Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax as of December 31: | |||
| Cumulative foreign currency translation (loss) adjustments | (4,859) | (4,924) | (4,912) |
| Net actuarial (losses) and prior service (cost) and credits | (3,871) | (3,540) | (2,726) |
| Cumulative (losses) gains on derivative instruments designated as cash flow hedges | (216) | (1) | 52 |
| Accumulated other comprehensive income (loss) | (8,946) | (8,465) | (7,586) |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2020 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2020 10-K (Filed: Feb 19, 2021) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $ 4,495 | 3,687 | 2,368 |
| Adjustments to reconcile earnings to net cash from operating activities - | |||
| Depreciation | 1,195 | 1,078 | 1,100 |
| Amortization of intangible assets | 2,132 | 1,936 | 2,178 |
| Share-based compensation | 546 | 519 | 477 |
| Amortization of inventory step-up | 32 | ||
| Investing and financing losses, net | 425 | 184 | 126 |
| Loss on extinguishment of debt | 63 | 167 | |
| Trade receivables | (924) | (275) | (190) |
| Inventories | (493) | (593) | (514) |
| Prepaid expenses and other assets | (627) | (138) | 23 |
| Trade accounts payable and other liabilities | 1,766 | 220 | 747 |
| Income taxes | (614) | (545) | (214) |
| Net Cash From Operating Activities | 7,901 | 6,136 | 6,300 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of property and equipment | (2,177) | (1,638) | (1,394) |
| Acquisitions of businesses and technologies, net of cash acquired | (42) | (170) | (54) |
| Proceeds from business dispositions | 58 | 48 | 48 |
| Purchases of investment securities | (83) | (103) | (131) |
| Proceeds from sales of investment securities | 10 | 21 | 73 |
| Other | 19 | 27 | 102 |
| Net Cash From (Used in) Investing Activities | (2,215) | (1,815) | (1,356) |
| Cash Flow From (Used in) Financing Activities: | |||
| Proceeds from issuance of (repayments of) short-term debt, net and other | 2 | (26) | |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 1,281 | 1,842 | 4,009 |
| Repayments of long-term debt and debt with maturities over 3 months | (1,333) | (3,441) | (12,433) |
| Purchases of common shares | (403) | (718) | (238) |
| Proceeds from stock options exercised | 245 | 298 | 271 |
| Dividends paid | (2,560) | (2,270) | (1,974) |
| Other | (11) | ||
| Net Cash From (Used in) Financing Activities | (2,779) | (4,289) | (10,391) |
| Effect of exchange rate changes on cash and cash equivalents | 71 | (16) | (116) |
| Net Increase (Decrease) in Cash and Cash Equivalents | 2,978 | 16 | (5,563) |
| Cash and Cash Equivalents, Beginning of Year | 3,860 | 3,844 | |
| Cash and Cash Equivalents, End of Year | 6,838 | 3,860 | 3,844 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | 970 | 930 | 740 |
| Interest paid | 549 | 677 | 845 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ABBOTT LABORATORIES | ||
Ticker: ABT Fiscal Year: 2020 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2020 10-K (Filed: Feb 19, 2021) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2020 | Dec 31, 2019 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $ 6,838 | 3,860 |
| Investments, primarily bank time deposits and U.S. treasury bills | 310 | 280 |
| Trade receivables, less allowances of - 2020: $460; 2019: $384 | 6,414 | 5,425 |
| Inventories: | ||
| Finished products | 3,030 | 2,784 |
| Work in process | 712 | 560 |
| Materials | 1,270 | 972 |
| Total inventories | 5,012 | 4,316 |
| Other prepaid expenses and receivables | 1,867 | 1,786 |
| Total current assets | 20,441 | 15,667 |
| Investments | 821 | 883 |
| Property and equipment, at cost: | ||
| Land | 538 | 519 |
| Buildings | 4,014 | 3,702 |
| Equipment | 12,884 | 11,468 |
| Construction in progress | 1,357 | 1,110 |
| Property and equipment, at cost | 18,793 | 16,799 |
| Less: accumulated depreciation and amortization | 9,764 | 8,761 |
| Net property and equipment | 9,029 | 8,038 |
| Intangible assets, net of amortization | 14,784 | 17,025 |
| Goodwill | 23,744 | 23,195 |
| Deferred income taxes and other assets | 3,729 | 3,079 |
| Total Assets | 72,548 | 67,887 |
| Liabilities and Shareholders' Investment | ||
| Current liabilities: | ||
| Short-term borrowings | 213 | 201 |
| Trade accounts payable | 3,946 | 3,252 |
| Salaries, wages and commissions | 1,416 | 1,237 |
| Other accrued liabilities | 5,165 | 4,035 |
| Dividends payable | 798 | 635 |
| Income taxes payable | 362 | 226 |
| Current portion of long-term debt | 7 | 1,277 |
| Total current liabilities | 11,907 | 10,863 |
| Long-term debt | 18,527 | 16,661 |
| Post-employment obligations and other long-term liabilities | 9,111 | 9,062 |
| Commitments and Contingencies | ||
| Shareholders' Investment: | ||
| Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued | ||
| Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2020: 1,981,156,896; 2019: 1,976,855,085 | 24,145 | 23,853 |
| Common shares held in treasury, at cost - Shares: 2020: 209,926,622; 2019: 214,351,838 | (10,042) | (10,147) |
| Earnings employed in the business | 27,627 | 25,847 |
| Accumulated other comprehensive income (loss) | (8,946) | (8,465) |
| Total Abbott Shareholders' Investment | 32,784 | 31,088 |
| Noncontrolling interests in subsidiaries | 219 | 213 |
| Total Shareholders' Investment | 33,003 | 31,301 |
| Total Liabilities and Shareholders' Investment | 72,548 | 67,887 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2020 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |